SNS-032 Injection

DRUG2 trials

Sponsors

Sunesis Pharmaceuticals

Conditions

B-lymphoid MalignanciesChronic Lymphocytic LeukemiaMantle Cell LymphomaMultiple MyelomaTumors

Phase 1

Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors

CompletedNCT00292864

Sunesis PharmaceuticalsTumors

Start: 2006-01-31End: 2007-12-31Target: 25Updated: 2012-06-07

Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies

CompletedNCT00446342

Sunesis PharmaceuticalsB-lymphoid Malignancies, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma +1

Start: 2007-02-28End: 2009-03-31Updated: 2017-04-11